Recently, the frontier drug INT230-6 showed good tumour killing effects in the treatment of soft tissue sarcoma in the single arm phase 1/2 open-label clinical trial IT-01 (NCT03058289), and the drug showed good responses whether injected inside the tumour alone or in combination with the CTLA-4 immune checkpoint inhibitor ipilimumab.
Apparatus
-
-
Biopharmaceutical company Airway has announced that the first patient will be administered AT-100 (rhSP-D) in a phase 1b randomised trial to prevent the risk of bronchopulmonary dysplasia (BPD) in very preterm infants. The novel prophylactic AT-100 reduces the incidence and severity of the severe respiratory disease BPD and may improve the prognosis of very preterm infants.
-
Apparatus
Cancer Vaccine Shows Its Power! Survival Of Patients With Advanced Colorectal Cancer Extended By More Than 3 Times!
Data from a study of a cancer vaccine combined with a PD-1 immune checkpoint inhibitor has recently been released, and the treatment has increased the survival of patients with advanced colorectal cancer by more than three times, with some patients surviving for more than 22 months so far.
-
Apparatus
Fujifilm Ai Technology Can Predict Whether Cognitive Disorders Will Progress To Alzheimer's Disease
Fujifilm Corporation and the National Center for Psychiatric and Neurological Research have announced positive research results using Fujifilm's new AI technology to predict whether a patient with mild cognitive impairment (MCI) will progress to Alzheimer's disease (AD) within two years.
-
Apparatus
Nature Medicine publishes results of H-drug combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma
H-Drugs in the leading international journal again!
-
In a rural area of Britain, a team of 100 scientists and engineers first used low-cost technologies to develop mobile phones and the aviation industry. Later, these technologies were used to research robot arms, which can be specially used for minimally invasive surgery.
-
New therapy for lung cancer!
-
Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!
-
The dental profession can use these tools as a guide to improve the sustainability of their working environment and to recognise their efforts by tracking progress.
-
Apparatus
Angry FDA & CDC: $5 Billion Bivalent Moderna New Crown Vaccine Not As Effective As Monovalent
Was the omission of key data intentional or unintentional?